CXCR3 and liver cancer: We analyzed CXCR3 pathway ssGSEA scores in patients with liver cancer, melanoma, and non-small cell lung cancer who received immunotherapy and found that CXCR3 pathway scores in the responder groups were significantly higher than those in the non-responder groups (Wilcoxon's test, GSE35640, p = 0.006; GSE14091, p = 0.0034; GSE93157, p = 0.095; GSE126044, p = 0.027; GSE135222, p = 0.084; PRJEB23709, p = 8.8e-06; Additional file 2: Figure S2G–L).